CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.
  
  LEARNING OBJECTIVES

  • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
  • Appreciate the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
  • Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of the mechanisms of action of, recent data with and current roles for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation.
  • Assess the FDA-approved indication for CPX-351 for patients with therapy-related or newly diagnosed AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
  • Formulate a treatment algorithm for patients with lower- and higher-risk myelodysplastic syndromes (MDS), considering patient- and disease-related factors including cytogenetic abnormalities.
  • Develop an understanding of the biologic rationale for and available data with emerging novel combination approaches for individuals with higher-risk MDS to prepare for their potential availability in routine practice.
  • Recall promising agents and strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY AND MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:
  
  Faculty
  Alice S Mims, MD, MSCR
  Acute Leukemia Clinical Research Director
  Associate Professor, Division of Hematology
  The Ohio State University Comprehensive Cancer Center
  Columbus, Ohio
  
  Advisory Committee: AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Kura Oncology, Syndax Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Aptevo Therapeutics, Astex Pharmaceuticals, Kartos Therapeutics, Karyopharm Therapeutics, Leukemia & Lymphoma Society, Plexxikon Inc, Xencor; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc; Other: Leukemia & Lymphoma Society — Senior Medical Director for the Beat AML study.
  
  Alexander Perl, MD
  Associate Professor of Medicine
  Perelman School of Medicine
  Member, Leukemia Program
  Abramson Cancer Center
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Syndax Pharmaceuticals Inc;Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Sumitomo Dainippon Pharma Oncology Inc;Contracted Research: AbbVie Inc, Astellas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc;Data and Safety Monitoring Board/Committee: Beat AML LLC, Leukemia & Lymphoma Society. 
  
  Richard M Stone, MD
  Professor of Medicine
  Harvard Medical School
  Chief of Staff
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, Arog Pharmaceuticals Inc, BerGenBio ASA, Boston Pharmaceuticals, Bristol-Myers Squibb Company, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Onconova Therapeutics Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.
  
  Geoffrey L Uy, MD
  Professor of Medicine
  Division of Oncology
  Washington University School of Medicine
  St Louis, Missouri
  
  No relevant conflicts of interest to disclose.
  
  Moderator
  
  Harry Paul Erba, MD, PhD
  Director, Leukemia Program
  Instructor in the Department of Medicine
  Member of the Duke Cancer Institute
  Duke University School of Medicine
  Durham, North Carolina
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Daiichi Sankyo Inc, FORMA Therapeutics, Forty Seven Inc, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, PTC Therapeutics; Independent Review Committee: AbbVie Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc and Servier Pharmaceuticals LLC.
  
  Release date: January 2022
  Expiration date: January 2023